{"pmid":32201354,"title":"SARS-CoV-2: fear versus data.","text":["SARS-CoV-2: fear versus data.","SARS-CoV-2, the novel coronavirus from China, is spreading around the world, causing a huge reaction despite its current low incidence outside China and the Far East. Four common coronaviruses are in current circulation and cause millions of cases worldwide. This article compares the incidence and mortality rates of these four common coronaviruses with those of SARS-COV-2 in Organisation for Economic Co-operation and Development countries. It is concluded that the problem of SARS-CoV-2 is probably being overestimated, as 2.6 million people die of respiratory infections each year compared with less than 4000 deaths for SARS-CoV-2 at the time of writing.","Int J Antimicrob Agents","Roussel, Yanis","Giraud-Gatineau, Audrey","Jimeno, Marie-Therese","Rolain, Jean-Marc","Zandotti, Christine","Colson, Philippe","Raoult, Didier","32201354"],"abstract":["SARS-CoV-2, the novel coronavirus from China, is spreading around the world, causing a huge reaction despite its current low incidence outside China and the Far East. Four common coronaviruses are in current circulation and cause millions of cases worldwide. This article compares the incidence and mortality rates of these four common coronaviruses with those of SARS-COV-2 in Organisation for Economic Co-operation and Development countries. It is concluded that the problem of SARS-CoV-2 is probably being overestimated, as 2.6 million people die of respiratory infections each year compared with less than 4000 deaths for SARS-CoV-2 at the time of writing."],"journal":"Int J Antimicrob Agents","authors":["Roussel, Yanis","Giraud-Gatineau, Audrey","Jimeno, Marie-Therese","Rolain, Jean-Marc","Zandotti, Christine","Colson, Philippe","Raoult, Didier"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32201354","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.ijantimicag.2020.105947","keywords":["COVID-19","Coronavirus","SARS-CoV-2"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1662090442925146112,"score":6.998814,"similar":[{"pmid":32173241,"title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.","text":["Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.","Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2.","J Microbiol Immunol Infect","Lai, Chih-Cheng","Liu, Yen Hung","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Yen, Muh-Yen","Ko, Wen-Chien","Hsueh, Po-Ren","32173241"],"abstract":["Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2."],"journal":"J Microbiol Immunol Infect","authors":["Lai, Chih-Cheng","Liu, Yen Hung","Wang, Cheng-Yi","Wang, Ya-Hui","Hsueh, Shun-Chung","Yen, Muh-Yen","Ko, Wen-Chien","Hsueh, Po-Ren"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173241","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.jmii.2020.02.012","keywords":["2019-nCoV","Acute respiratory disease","Asymptomatic carrier","COVID-19","Coronavirus","SARS-CoV-2","Wuhan pneumonia"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1661456248797659136,"score":83.849144},{"pmid":32129518,"title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","text":["Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.","Drug Dev Res","Gurwitz, David","32129518"],"abstract":["At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility."],"journal":"Drug Dev Res","authors":["Gurwitz, David"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32129518","week":"202010|Mar 02 - Mar 08","doi":"10.1002/ddr.21656","keywords":["AT1R blockers","COVID-19 epidemic","SARS-CoV-2","angiotensin-converting enzyme 2 (ACE2)","losartan"],"source":"PubMed","locations":["losartan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1661359647676694528,"score":73.9468},{"pmid":32143990,"title":"The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China.","text":["The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China.","The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19. This viral epidemic in China has led to the deaths of over 1800 people, mostly elderly or those with an underlying chronic disease or immunosuppressed state. This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002-2003 and MERS in 2012. While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 may present with varying degrees of severity, from flu-like symptoms to death. It is currently believed that this deadly Coronavirus strain originated from wild animals at the Huanan market in Wuhan, a city in Hubei province. Bats, snakes and pangolins have been cited as potential carriers based on the sequence homology of CoV isolated from these animals and the viral nucleic acids of the virus isolated from SARS-CoV-2 infected patients. Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes, were instituted in January 2020 to prevent spread of the virus, but by that time much of the damage had been done, as human-human transmission became evident. While these quarantine measures are necessary and have prevented a historical disaster along the lines of the Spanish flu, earlier recognition and earlier implementation of quarantine measures may have been even more effective. Lessons learned from SARS resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy. However, it is clear that finding an effective antiviral and developing a vaccine are still significant challenges. The costs of the epidemic are not limited to medical aspects, as the virus has led to significant sociological, psychological and economic effects globally. Unfortunately, emergence of SARS-CoV-2 has led to numerous reports of Asians being subjected to racist behavior and hate crimes across the world.","J Autoimmun","Yang, Yongshi","Peng, Fujun","Wang, Runsheng","Guan, Kai","Jiang, Taijiao","Xu, Guogang","Sun, Jinlyu","Chang, Christopher","32143990"],"abstract":["The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19. This viral epidemic in China has led to the deaths of over 1800 people, mostly elderly or those with an underlying chronic disease or immunosuppressed state. This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002-2003 and MERS in 2012. While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 may present with varying degrees of severity, from flu-like symptoms to death. It is currently believed that this deadly Coronavirus strain originated from wild animals at the Huanan market in Wuhan, a city in Hubei province. Bats, snakes and pangolins have been cited as potential carriers based on the sequence homology of CoV isolated from these animals and the viral nucleic acids of the virus isolated from SARS-CoV-2 infected patients. Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes, were instituted in January 2020 to prevent spread of the virus, but by that time much of the damage had been done, as human-human transmission became evident. While these quarantine measures are necessary and have prevented a historical disaster along the lines of the Spanish flu, earlier recognition and earlier implementation of quarantine measures may have been even more effective. Lessons learned from SARS resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy. However, it is clear that finding an effective antiviral and developing a vaccine are still significant challenges. The costs of the epidemic are not limited to medical aspects, as the virus has led to significant sociological, psychological and economic effects globally. Unfortunately, emergence of SARS-CoV-2 has led to numerous reports of Asians being subjected to racist behavior and hate crimes across the world."],"journal":"J Autoimmun","authors":["Yang, Yongshi","Peng, Fujun","Wang, Runsheng","Guan, Kai","Jiang, Taijiao","Xu, Guogang","Sun, Jinlyu","Chang, Christopher"],"date":"2020-03-08T11:00:00Z","year":2020,"_id":"32143990","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.jaut.2020.102434","keywords":["Bats","Coronavirus","Epidemic","Epidemiology","Flu","Human to human transmission","Pandemic","Pneumonia","Pyroptosis","SARS-CoV","SARS-CoV-2"],"source":"PubMed","locations":["Huanan","Asians","Hubei","Spanish","Wuhan","China"],"countries":["China","Spain"],"countries_codes":["CHN|China","ESP|Spain"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1661359647762677761,"score":73.04374},{"pmid":32112977,"title":"World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).","text":["World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).","An unprecedented outbreak of pneumonia of unknown aetiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus was identified as the causative agent and was subsequently termed COVID-19 by the World Health Organization (WHO). Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is caused by a betacoronavirus named SARS-CoV-2 that affects the lower respiratory tract and manifests as pneumonia in humans. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with 90,870 laboratory-confirmed cases and over 3,000 deaths worldwide. In response to this global outbreak, we summarise the current state of knowledge surrounding COVID-19.","Int J Surg","Sohrabi, Catrin","Alsafi, Zaid","O'Neill, Niamh","Khan, Mehdi","Kerwan, Ahmed","Al-Jabir, Ahmed","Iosifidis, Christos","Agha, Riaz","32112977"],"abstract":["An unprecedented outbreak of pneumonia of unknown aetiology in Wuhan City, Hubei province in China emerged in December 2019. A novel coronavirus was identified as the causative agent and was subsequently termed COVID-19 by the World Health Organization (WHO). Considered a relative of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), COVID-19 is caused by a betacoronavirus named SARS-CoV-2 that affects the lower respiratory tract and manifests as pneumonia in humans. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with 90,870 laboratory-confirmed cases and over 3,000 deaths worldwide. In response to this global outbreak, we summarise the current state of knowledge surrounding COVID-19."],"journal":"Int J Surg","authors":["Sohrabi, Catrin","Alsafi, Zaid","O'Neill, Niamh","Khan, Mehdi","Kerwan, Ahmed","Al-Jabir, Ahmed","Iosifidis, Christos","Agha, Riaz"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32112977","week":"20209|Feb 24 - Mar 01","doi":"10.1016/j.ijsu.2020.02.034","keywords":["COVID-19","Global health emergency","Novel coronavirus","Viral transmission","Wuhan"],"source":"PubMed","locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647961907200,"score":72.00212},{"pmid":32176808,"title":"Potential impact of seasonal forcing on a SARS-CoV-2 pandemic.","text":["Potential impact of seasonal forcing on a SARS-CoV-2 pandemic.","A novel coronavirus (SARS-CoV-2) first detected in Wuhan, China, has spread rapidly since December 2019, causing more than 100,000 confirmed infections and 4000 fatalities (as of 10 March 2020). The outbreak has been declared a pandemic by the WHO on Mar 11, 2020. Here, we explore how seasonal variation in transmissibility could modulate a SARS-CoV-2 pandemic. Data from routine diagnostics show a strong and consistent seasonal variation of the four endemic coronaviruses (229E, HKU1, NL63, OC43) and we parameterise our model for SARS-CoV-2 using these data. The model allows for many subpopulations of different size with variable parameters. Simulations of different scenarios show that plausible parameters result in a small peak in early 2020 in temperate regions of the Northern Hemisphere and a larger peak in winter 2020/2021. Variation in transmission and migration rates can result in substantial variation in prevalence between regions. While the uncertainty in parameters is large, the scenarios we explore show that transient reductions in the incidence rate might be due to a combination of seasonal variation and infection control efforts but do not necessarily mean the epidemic is contained. Seasonal forcing on SARS-CoV-2 should thus be taken into account in the further monitoring of the global transmission. The likely aggregated effect of seasonal variation, infection control measures, and transmission rate variation is a prolonged pandemic wave with lower prevalence at any given time, thereby providing a window of opportunity for better preparation of health care systems.","Swiss Med Wkly","Neher, Richard A","Dyrdak, Robert","Druelle, Valentin","Hodcroft, Emma B","Albert, Jan","32176808"],"abstract":["A novel coronavirus (SARS-CoV-2) first detected in Wuhan, China, has spread rapidly since December 2019, causing more than 100,000 confirmed infections and 4000 fatalities (as of 10 March 2020). The outbreak has been declared a pandemic by the WHO on Mar 11, 2020. Here, we explore how seasonal variation in transmissibility could modulate a SARS-CoV-2 pandemic. Data from routine diagnostics show a strong and consistent seasonal variation of the four endemic coronaviruses (229E, HKU1, NL63, OC43) and we parameterise our model for SARS-CoV-2 using these data. The model allows for many subpopulations of different size with variable parameters. Simulations of different scenarios show that plausible parameters result in a small peak in early 2020 in temperate regions of the Northern Hemisphere and a larger peak in winter 2020/2021. Variation in transmission and migration rates can result in substantial variation in prevalence between regions. While the uncertainty in parameters is large, the scenarios we explore show that transient reductions in the incidence rate might be due to a combination of seasonal variation and infection control efforts but do not necessarily mean the epidemic is contained. Seasonal forcing on SARS-CoV-2 should thus be taken into account in the further monitoring of the global transmission. The likely aggregated effect of seasonal variation, infection control measures, and transmission rate variation is a prolonged pandemic wave with lower prevalence at any given time, thereby providing a window of opportunity for better preparation of health care systems."],"journal":"Swiss Med Wkly","authors":["Neher, Richard A","Dyrdak, Robert","Druelle, Valentin","Hodcroft, Emma B","Albert, Jan"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32176808","week":"202012|Mar 16 - Mar 22","doi":"10.4414/smw.2020.20224","source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Epidemic Forecasting"],"weight":1,"_version_":1661456248846942208,"score":71.96601}]}